CTRI/2022/07/043752已完成未知
A Prospective, Interventional, open label, Multicentric study to evaluate the efficacy and safety ofSilverNovaTM Skin Cream in Post aesthetic skin procedures subjects. - NI
Viridis BioPharma Pvt Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female subject between the age of 18 to 45 years.
- •2. Patients must have undergone Post aesthetic skin procedures which include: Chemical peeling (Tri Chloroacetic acid (TCA) cross peel, Yellow peel, Black peel, Glycolic peel etc.), Laser hair removal and Microneedling radiofrequency for atrophic acne scars.
- •3. The subjects were of general good health, had no obvious skin disease, known history of atopic dermatitis and/or skin elastosis on the face.
- •4. Subjects must be able to read, understand and provide written informed consent.
- •5. Individuals must agree to refrain from using any new products other than the assigned test materials.
- •6. Willingness not to use any moisturizer, cleanser, and/or sunscreen on the face other than the provided study product.
- •7. Subjects must agree to avoid excessive sun exposure and the use of artificial tanning methods.
- •8. Subjects must agree to arrive at their study visits with a clean face and without any products (lotions, creams, makeup, etc.) applied to their face.
- •9. Sexually active females of childbearing potential participating in the study must agree to use a medically-acceptable method of contraception while receiving study product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.
- •10. Subjects free of any acute or chronic illness/disease that might interfere with or increase risk of study participation.
- •11. Subjects with no known allergy to any of the external applications
排除标准
- •1. Any dermatological disorder that, in the investigatorâ??s opinion, may interfere with the accurate evaluation of the subjectâ??s face.
- •2. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.
- •3. Concurrent therapy with any medication, either topical or oral, that might interfere with the study.
- •4. Subjects who have used a topical retinoid or other cosmeceutical preparation within 2 weeks of study enrollment, to include kojic acid, vitamin C, licorice extracts, alpha hydroxy acids etc.
研究者
相似试验
尚未招募
3 期
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentCTRI/2024/07/069956Pfizer Inc.
暂停
3 期
A clinical study to evaluate the efficacy and safety of immunoglobulin intravenous (human) 10% (NewGam) in Primary Immune Thrombocytopenia, Is the condition of having an abnormally low platelet count (thrombocytopenia) of no known cause.CTRI/2011/11/002098OCTAPHARMA AG95
已完成
2 期
Clinical study on JP-16 Capsules in impotencyCTRI/2017/09/009618Chatarubhuj Pharmaceutical Co40
已完成
2 期
Clinical study on IMPERIM® Capsule in erectile dysfunction.CTRI/2019/09/021217Dr Bioveda Lab
已完成
2 期
Clinical study on Ayuvigo Forte Capsule in erectile dysfunctioCTRI/2017/08/009425Welex Laboratories Pvt Ltd38